

PRESS RELEASE

CORDLIFE RECEIVES FACT ACCREDITATION

- ***FACT accreditation showcases Cordlife's commitment to the highest standards of quality and excellence***
- ***Cordlife achieves the double-accreditation status from AABB and FACT-NETCORD which helped put Singapore on the world map by being one out of the six dual-accredited private cord blood banks worldwide.***

Singapore, 5 January 2016 – Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), a mother and child consumer healthcare company, announced that it has been accredited by the Foundation for the Accreditation of Cellular Therapy (“FACT”) for the next two years. With this new accreditation, Cordlife becomes the first private cord blood bank in Singapore and South East Asia that fulfils two world-class accreditation standards. Cordlife has grown to become the dominant private cord blood bank operator in the region, and internationally, it joins five other private cord blood banks to have dual-accreditation. The FACT accreditation is a testament to Cordlife’s unrivalled commitment to delivering superior standards in patient care and laboratory practices.

Founded in 1996, FACT is a non-profit corporation focusing on the establishment of high quality medical and laboratory practices in cellular therapies. The voluntary FACT accreditation program is founded upon a network of peers helping each other improve cellular therapy practices. Rigorous and comprehensive inspections are balanced with a collegial approach that encourages organizations to reach minimum standards for the benefit of patients. The FACT standards are evidence-based requirements set by world-renowned experts vested in the improvement and progress of cellular therapy. Today, FACT is the only accrediting agency that addresses all quality aspects of cellular therapy and cord blood banking including collection, processing, and administration.

Mr. Jeremy Yee, Executive Director and Chief Executive Officer of Cordlife said: “We are delighted to announce that with this accreditation, we have achieved yet another milestone which highlights the Group’s unwavering commitment to enhancing the quality of our

facilities and operations. As Southeast Asia's leader in the cord blood banking industry and consumer healthcare space, we pride ourselves on delivering the highest quality of products and services to our clients. The FACT accreditation will provide both physicians and families the assurance that Cordlife will continue to adhere to the gold standards of the industry".

- The End -

ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited ("Cordlife", and together with its subsidiaries, the "Group"), is a consumer healthcare company catering to the mother and child segment and a leading cord blood and umbilical cord lining banking services provider. Amongst the first private cord blood banks in Asia, Cordlife has the largest market share of private cord blood banks in Singapore, Indonesia and the Philippines¹. In Hong Kong and India, it is amongst the top three market leaders for private cord blood banks.

Cordlife, through its collaborative relationships and arrangements with major private hospitals and clinics such as Thomson Medical and Parkway East Hospital, has continued to increase public awareness of its cord blood banking service in Singapore. In October 2013, Cordlife also acquired a 19.92% stake in StemLife Berhad ("StemLife"), a fully licensed cord blood banking facility with the Ministry of Health Malaysia listed on the ACE Market of Bursa Malaysia. In December 2015, Cordlife has increased its interest to approximately 80.86%, becoming the major shareholder of StemLife.

Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks) and also has been accredited by the Foundation for the Accreditation of Cellular Therapy ("FACT") in 2015, becoming the first dual-accredited cord blood bank in South East Asia. The Group is one of the first private cord blood banks to have released cord blood units for transplants, for treatment of cerebral palsy as well as for other therapeutic uses. In addition, in April 2013, Cordlife became the first private cord blood bank in Asia to have launched a GMP compliant automated stem cell processing system that maximises automation while ensuring consistently high cell recoveries. Cordlife also has a strategic alliance in China with CordLabs Asia Pte. Ltd., a wholly-owned subsidiary of CellResearch Corporation Pte. Ltd., which gives the Group the exclusive rights to market their technology in relation to the provision of human postnatal cord lining storage services and training and the transfer of the know-how, in India, Indonesia, Malaysia, Philippines, Singapore, Hong Kong and Thailand.

Cordlife's track record has won the Group many accolades and awards, including: "My Favourite Cord Blood Bank" by Hong Kong Economic Times; 2014 Most Popular Stem Cell Bank Reader's Choice by Child Magazine. In August 2013, Cordlife was presented with Merit Award for the Singapore Corporate Awards 2013, "Best Investor Relations Award". In November 2013, Cordlife was named the "Most Transparent Company 2013" in the Retail & Household Goods Category and Mainboard Small Caps Category at the 14th SIAS Investors' Choice Awards. In October 2015, named as the Runner-up of the 16th SIAS Investors' Choice Award, Singapore Corporate Governance Award (SCGA) 2015, Mid and Small Category. Cordlife was also honoured by Forbes Asia as one of the "Best Under a Billion" companies at an awards ceremony and dinner held in November 2015.

¹ Source: Deloitte & Touche Financial Advisory Services Limited report, October 2014

ISSUED ON BEHALF OF	:	Cordlife Group Limited
BY	:	Financial PR Pte Ltd 4 Robinson Road #04-01 The House of Eden Singapore 048543
CONTACT	:	Mr Kamal Samuel / Mr Mark Lin
OFFICE	:	6438-2990
EMAIL	:	kamal@financialpr.com.sg / marklin@financialpr.com.sg
